Saluda Medical Revenue Rises 26% as US Patient Implants Jump 55%
SLD: $0.255 -3.77% · MC: $58M
Saluda Medical reported September-quarter revenue of approximately US$23 million, up 26% year on year, while US patient implants rose 55%; revenue was down from the prior quarter’s record, which the company attributed partly to seasonal softness and deferred revenue recognised in that quarter. US revenue grew faster than international revenue, but lagged patient growth as some customers used inventory bought earlier and account mix shifted. The company reaffirmed FY27 guidance and said it expects operating cash use to ease after the first quarter, when cash and available facilities totalled approximately US$99 million.

Comments